TAGAMET
LOE ApproachingNDAORALSOLUTIONPriority Review
Approved
Aug 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAGAMET is a small-molecule oral solution approved in 1977 by GSK. The generic name and specific mechanism of action are not provided in available data, but the product represents a foundational oral therapeutic. This legacy product serves a defined patient population with established clinical utility.
LOE Approaching
Product faces near-term loss of exclusivity with moderate competitive pressure (30/100), signaling potential team downsizing and focus shift to lifecycle extension or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an approaching LOE, TAGAMET offers limited growth opportunity and likely represents a career consolidation or exit point. Professionals on this team should prepare for organizational restructuring or explore transfer to growth-stage assets within GSK's portfolio.
Brand ManagerCommercial Operations Analyst
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.